Pegylated mechano growth factor (MGF), an IGF-1 splice variant peptide
PEG-MGF is a longer-lasting, pegylated version of mechano growth factor, a muscle-specific splice variant of IGF-1.
| Class / type | Pegylated mechano growth factor (MGF), an IGF-1 splice variant peptide |
|---|---|
| Category | Growth Hormone & Muscle |
| Status (Jul 2026) | Research use only |
MGF (the IGF-1Ec E-peptide) activates quiescent muscle satellite (stem) cells to proliferate after mechanical stress or damage; attaching polyethylene glycol (PEG) extends its half-life from minutes to days.
Researched for muscle regeneration, tissue repair, and recovery from muscle damage; no approved clinical use exists.
Longer circulating half-life than native MGF, and studied potential to promote satellite cell proliferation and localized muscle repair.
No human clinical trials or established safety data, unknown long-term effects, theoretical tissue-growth and tumor-promotion concerns tied to IGF signaling, and product purity concerns in the research-chemical market.
Users report perceived improvements in muscle recovery and localized fullness; anecdotal sentiment only, not an endorsement.
NOT FDA-approved. It is a research-only peptide with no pharmaceutical approval for human use and is prohibited by WADA at all times under class S2.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.